54 related articles for article (PubMed ID: 11935211)
1. Factors influencing the cellular accumulation of SN-38 and camptothecin.
Cummings J; Boyd G; Macpherson JS; Wolf H; Smith G; Smyth JF; Jodrell DI
Cancer Chemother Pharmacol; 2002 Mar; 49(3):194-200. PubMed ID: 11935211
[TBL] [Abstract][Full Text] [Related]
2. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
[TBL] [Abstract][Full Text] [Related]
3. High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells.
Boyd G; Smyth JF; Jodrell DI; Cummings J
Anal Biochem; 2001 Oct; 297(1):15-24. PubMed ID: 11567523
[TBL] [Abstract][Full Text] [Related]
4. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Cummings J; Boyd G; Ethell BT; Macpherson JS; Burchell B; Smyth JF; Jodrell DI
Biochem Pharmacol; 2002 Feb; 63(4):607-13. PubMed ID: 11992628
[TBL] [Abstract][Full Text] [Related]
5. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
[TBL] [Abstract][Full Text] [Related]
7. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.
Cummings J; Zelcer N; Allen JD; Yao D; Boyd G; Maliepaard M; Friedberg TH; Smyth JF; Jodrell DI
Biochem Pharmacol; 2004 Jan; 67(1):31-9. PubMed ID: 14667926
[TBL] [Abstract][Full Text] [Related]
8. Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).
Lalloo AK; Luo FR; Guo A; Paranjpe PV; Lee SH; Vyas V; Rubin E; Sinko PJ
BMC Med; 2004 May; 2():16. PubMed ID: 15125776
[TBL] [Abstract][Full Text] [Related]
9. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
10. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
11. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.
Larsen AK; Gilbert C; Chyzak G; Plisov SY; Naguibneva I; Lavergne O; Lesueur-Ginot L; Bigg DC
Cancer Res; 2001 Apr; 61(7):2961-7. PubMed ID: 11306474
[TBL] [Abstract][Full Text] [Related]
12. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.
Chauvier D; Kegelaer G; Morjani H; Manfait M
J Pharm Sci; 2002 Aug; 91(8):1765-75. PubMed ID: 12115804
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.
Zastre J; Anantha M; Ramsay E; Bally M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):91-102. PubMed ID: 17009029
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines.
te Poele RH; Joel SP
Br J Cancer; 1999 Dec; 81(8):1285-93. PubMed ID: 10604724
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin.
Niimi S; Nakagawa K; Sugimoto Y; Nishio K; Fujiwara Y; Yokoyama S; Terashima Y; Saijo N
Cancer Res; 1992 Jan; 52(2):328-33. PubMed ID: 1345810
[TBL] [Abstract][Full Text] [Related]
17. Characterization of secretory intestinal transport of the lactone form of CPT-11.
Takemoto I; Itagaki S; Chiba M; Itoh T; Hirano T; Iseki K
Cancer Chemother Pharmacol; 2006 Jan; 57(1):129-33. PubMed ID: 16003561
[TBL] [Abstract][Full Text] [Related]
18. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
19. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.
Ohishi Y; Oda Y; Uchiumi T; Kobayashi H; Hirakawa T; Miyamoto S; Kinukawa N; Nakano H; Kuwano M; Tsuneyoshi M
Clin Cancer Res; 2002 Dec; 8(12):3767-75. PubMed ID: 12473588
[TBL] [Abstract][Full Text] [Related]
20. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.
Materna V; Pleger J; Hoffmann U; Lage H
Gynecol Oncol; 2004 Jul; 94(1):152-60. PubMed ID: 15262134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
